Pitavastatin calcium: Clinical review of a new antihyperlipidemic medication

Clinical Therapeutics

Volumn 33, Issue 8, 2011, Pages 1023-1042

  Yee, Laurie L ^a   Wright, Eric A ^a  

^a WILKES UNIVERSITY   (United States)

Author keywords

Cholesterol; HMG CoA reductase inhibitors; Livalo; Low density lipoprotein; Pitavastatin; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CYTOCHROME P450 3A; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; MEVACO; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ATHEROSCLEROSIS; CONTROLLED STUDY; DIPLOPIA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG TOLERABILITY; EDEMA; EMBASE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INDIGESTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDLINE; MYALGIA; MYOPATHY; PAIN; REVIEW; SIDE EFFECT; VOMITING;

ANIMALS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; QUINOLINES; TRIGLYCERIDES;

EID: 80051659998     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.07.011     Document Type: Review

References (60)

1. Lamb E. Top 200 drugs of 2008. Pharmacy Times 2009.
2. Pfizer 2009 Annual Report Accessed April 5, 2010. http://media.pfizer.com/files/annualreport/2009/financial/financial2009.pdf.
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults.
4. Livalo (pitavastatin) [product information] 2009, Kowa Pharmaceuticals America, Inc, Montgomery, Ala.
5. Shitara Y., Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112:71-105.
6. Aoki T., Nishimura H., Nakagawa S., et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 1997, 47:904-909.
7. Morikawa S., Umetani M., Nakagawa S., et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000, 7:138-144.
8. Fan P., Zhang B., Kuroki S., Saku K. Pitavastatin, a potent hydroxymethylglutaryl coenzyme a reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells. Circ J 2004, 68:1061-1066.
9. Maejima T., Yamazaki H., Aoki T., et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004, 324:835-839.
10. Saiki A., Murano T., Watanabe F., et al. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 2005, 12:163-168.
11. Fujino H., Kojima J., Yamada Y., Kanda H. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): interspecies variation in laboratory animals and humans. Drug Metab Pharmacokinetics 1999, 14:79-91.
12. Kimata H., Fujino H., Koide H., et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): absorption, distribution, metabolism and excretion in rats. Drug Metab Pharmacokinetics 1998, 13:484-499.
13. Fujino H., Tsunenari Y., Koide T., et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (2): absorption, distribution, metabolism, excretion and accumulation following repeated oral administration of 14C-NK-104 in rats. Drug Metab Pharmacokinetics 1998, 13:499-507.
14. Fujino H., Yamada I., Kojima J., et al. Studies on metabolic fate of NK-104, a new inhibitor of HMG-CoAQ reductase (5): in vitro metabolism and plasma protein binding in animals and humans. Xenobio Metabol Dispos 1999, 14:415-425.
15. Kojima J., Fujino H., Yosimura M., et al. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1999, 724:173-180.
16. Kojima J., Fujino H., Abe H., et al. Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull 1999, 22:142-150.
17. Fujino H., Yamada I., Kojima J., et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human. Drug Metab Pharmacokinetics 1999, 14:415-424.
18. Fujino H., Saito T., Tsunenari Y., Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin--determining the best animal model for human CYP and UGT activities. Drug Metabol Drug Interact 2004, 20:25-42.
19. Kojima J., Ohshima T., Yoneda M., Sawada H. Effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs. Drug Metab Pharmacokinetics 2001, 16:497-502.
20. Fujino H., Saito T., Tsunenari Y., et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 2004, 34:961-971.
21. Fujino H., Nakai D., Nakagomi R., et al. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung 2004, 54:382-388.
22. Hirano M., Maeda K., Shitara Y., Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004, 311:139-146.
23. Hui C.K., Cheung B.M., Lau G.K. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol 2005, 59:291-297.
24. Hirano M., Maeda K., Shitara Y., Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006, 34:1229-1236.
25. Ando H., Tsuruoka S., Yanagihara H., et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 2005, 60:494-497.
26. Inagaki Y., Hunt T., Arana B., et al. Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers. J Clin Pharmacol 2011 January 12, [Epub ahead of print].
27. Saito Y., Yamada N., Teramoto T., et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 2002, 52:251-255.
28. Sansanayudh N., Wongwiwatthananukit S., Putwai P., Dhumma-Upakorn R. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Ann Pharmacother 2010, 44:415-423.
29. Budinski D., Arneson V., Hounslow N., Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009, 4:291-302.
30. Lee S.H., Chung N., Kwan J., et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther 2007, 29:2365-2373.
31. Yokote K., Bujo H., Hanaoka H., et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008, 201:345-352.
32. Sasaki J., Ikeda Y., Kuribayashi T., et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008, 30:1089-1101.
33. Toi T., Taguchi I., Yoneda S., et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ J 2009, 73:1466-1472.
34. Sakabe K., Fukuda N., Fukuda Y., et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol 2008, 125:136-138.
35. Saito Y., Yamada N., Teramoto T., et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002, 162:373-379.
36. Yanagi K., Monden T., Ikeda S., et al. A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes. Adv Ther 2011, 28:160-171.
37. Ose L., Budinski D., Hounslow N., Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009, 25:2755-2764.
38. Park S., Kang H.J., Rim S.J., et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther 2005, 27:1074-1082.
39. Hiro T., Kimura T., Morimoto T., et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009, 54:293-302.
40. Mahley R.W., Innerarity T.L., Rall S.C., Weisgraber K.H. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984, 25:1277-1294.
41. Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(Suppl 1):S11-S61. American Diabetes Association.
42. Fukutomi T., Takeda Y., Suzuki S., et al. High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor. Int J Cardiol 2010, 141:320-322.
43. Noji Y., Higashikata T., Inazu A., et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002, 163:157-164.
44. Kawashiri M.A., Nohara A., Tada H., et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther 2008, 83:731-739.
45. Ridker P.M., Danielson E., Fonseca F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
46. Lorenz M.W., Markus H.S., Bots M.L., et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
47. Mizuguchi Y., Oishi Y., Miyoshi H., et al. Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circ J 2008, 72:538-544.
48. Ono K., Kawasaki M., Tanaka R., et al. Integrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: effect of pitavastatin therapy. Ultrasound Med Biol 2009, 35:193-200.
49. Nakamura T., Obata J.E., Kitta Y., et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol 2008, 51:365-371.
50. Miyauchi H., Kimura T., Morimoto T., et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design. Circ J 2006, 70:1624-1628.
51. Arai H., Hiro T., Kimura T., et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome-sub-analysis of JAPAN-ACS study. J Atheroscler Thromb 2010, 17:1096-1107.
52. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
53. Kurihara Y., Douzono T., Kawakita K. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (Livalo tablet)-Livalo Effectiveness and Safety (LIVES) Study. Jpn Pharmacol Ther 2008, 36:709-731.
54. Ose L., Budinski D., Hounslow N., Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010, 210:202-208.
55. Klein B.E.K., Klein R., Lee K.E., Grady L.M. Statin use and incident nuclear cataract. JAMA 2006, 295:2752-2758.
56. Mood G.R., Bavry A.A., Roukoz H., Bhatt D.L. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol 2007, 100:919-923.
57. Murphy S.A., Cannon C.P., Wiviott S.D., et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the aggrastat to Zocor and pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 trials). Am J Cardiol 2007, 100:1047-1051.
58. Pedersen T.R., Faergeman O., Kastelein J.J.P., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
59. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002, 346:539-a.
60. Mizuma H., Inoue T., Takano H., et al. Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study). Int J Cardiol 2010 November 12, [Epub ahead of print].